Bone Growth Stimulator Global Market Report 2024

A bone growth stimulator (BGS) is a device designed to enhance the natural fusion of bones following a fracture. The primary goal of BGS is to deliver increased energy to the healing bone surface, achieved through either pulsed electromagnetic or ultrasound methods. In the case of pulsed electromagnetic fields, the BGS attracts the oppositely charged ends of the bones, stimulating new bone growth and fusion, ultimately promoting the healing process. Bone growth stimulators are employed to aid in bone healing for challenging fractures or fusions by applying ultrasonic or electrical current to the fracture or fusion site.

The main types of bone growth stimulators (BGS) include bone growth stimulation devices, bone morphogenetic proteins (BMP), and platelet-rich plasma (PRP) therapy. Bone growth stimulation devices can be either implanted internally or worn externally using straps to secure them in place, enhancing the rate and shortening the time required for fracture healing. These devices find application in the treatment of fractures, spinal fusion, osteogenesis, arthrodesis treatment, and spondylolisthesis. The primary end-use sectors for BGS include hospitals and ambulatory surgical centers (ASCs), specialty clinics, and home care.

The bone growth stimulators market research report is one of a series of new reports that provides bone growth stimulators market statistics, including bone growth stimulators industry global market size, regional shares, competitors with a bone growth stimulators market share, detailed bone growth stimulators market segments, market trends and opportunities, and any further data you may need to thrive in the bone growth stimulators industry. This bone growth stimulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bone growth stimulator market size has grown rapidly in recent years. It will grow from $1.53 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth observed during the historical period can be attributed to various factors, including an aging population with a higher incidence of orthopedic conditions, increased awareness of non-invasive treatments, expanded access to healthcare services, favorable reimbursement policies, a growing demand for minimally invasive solutions, and an increased prevalence of orthopedic surgeries.

The bone growth stimulator market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The anticipated growth in the forecast period can be attributed to factors such as heightened public awareness, increased adoption of regenerative medicine, investments in healthcare infrastructure, the expansion of applications and indications, and supportive healthcare policies. Noteworthy trends expected during this period include the continued development of regenerative medicine approaches, the utilization of 3D printing technology, the incorporation of wireless and IoT technologies for remote patient monitoring, a shift towards patient-centric care, and the increasing utilization of telemedicine in healthcare practices.

The bone growth stimulators market is expected to experience significant growth, primarily driven by the increasing number of bone fractures. Factors such as age, dietary habits, and chronic disorders can weaken bones, making them more susceptible to fractures. Overuse or repetitive motions can also contribute to bone fractures. In May 2022, Amgen, a U.S.-based biotechnology company, reported that osteoporosis leads to approximately 1.5 million fractures annually in the United States, resulting in associated expenses of $19 billion. Furthermore, it is projected that the number of osteoporotic fractures will increase by 68% annually from 2018 to 2040, reaching 3.2 million. The rising incidence of bone fractures is expected to be a significant driver for the growth of the bone growth stimulator market.

The growth of the bone growth stimulator market is also propelled by the increasing number of sports injuries. Sports injuries, which can affect various parts of the body, including bones, muscles, ligaments, and tendons, often require interventions to aid in bone repair and rehabilitation. Bone growth stimulators play a crucial role in promoting bone restoration, tissue growth, and overall healing in sports injuries. In 2022, the National Safety Council reported a 20% increase in sports and leisure injuries in 2021 and an additional 12% increase in 2022. The growing prevalence of sports injuries is contributing to the expansion of the bone growth stimulator market.

Technological advancement is a notable trend in the bone growth stimulators market, with a focus on innovative approaches such as Electrical Bone Growth Stimulation (EBGS). This unique method aims to accelerate healing and enhance fusion success rates. The increased adoption and experience with EBGS devices have led to significant advancements in stimulation paradigms and clinical outcomes. For example, in May 2022, Orthofix Medical Inc., a U.S.-based manufacturer of spinal, orthopedic, and bone development solutions, received pre-market approval from the U.S. Food and Drug Administration (FDA) for the AccelStim bone healing therapy Class III device. The AccelStim device, utilizing Low-Intensity Pulsed Ultrasound (LIPUS), provides a nonsurgical therapy option for new fractures and fractures that are still healing (nonunions), enhancing the natural healing process of the bone.

Leading companies in the bone growth stimulator market are prioritizing innovative product approvals, as evidenced by the patent approval of the ActaStim-S Spine Fusion Bone Growth Stimulator system. This system is a non-invasive device designed to stimulate bone repair and fusion following spinal fusion surgery. Notable features include a cordless design and a user-friendly mobile app. It has received approval from the U.S. Food and Drug Administration (FDA) for use after spinal fusion procedures or to treat a failed fusion from a previous operation. In August 2022, Theragen, Inc., a U.S.-based pharmaceutical and biotechnology company, announced the successful acquisition of a U.S. patent for its groundbreaking ActaStim-S Spine Fusion Bone Growth Stimulator system. ActaStim-S is a revolutionary spine fusion stimulator, incorporating clinically proven therapeutic stimulation with modern design and a data-rich digital health platform. This approach not only enhances the healing process but also promotes patient compliance, engagement, and informed communication with healthcare practitioners during the crucial post-operative fusion phase.

In March 2021, Binoventus, a U.S.-based company specializing in innovations for active healing, completed the acquisition of Bioness Inc. for $45 million in upfront consideration, with an additional $65 million contingent upon achieving specific milestones. With this strategic acquisition, Bioventus gained access to the complete portfolio of Bioness products, including its research and development pipeline. Bioness Inc., based in Spain, is a medical equipment manufacturing company offering products related to bone healing and the efficacy of bone grafts for treating osteoarthritis. This acquisition reinforces Bioventus' position in the bone growth stimulator market and broadens its offerings in the field of active healing solutions.

Major companies operating in the bone growth stimulator market include Arthrex Inc., DJO Global Inc., Stryker Corporation, Bioventus LLC, Zimmer Biomet Holdings Inc., 3M Company, Ambu A/S, Becton Dickinson and Company, Cognionics Inc., ConMed Corporation, The Cooper Companies Inc., DyMedix Corporation, Koninklijke Philips N.V., Medtronic PLC, Natus Medical Incorporated, Terumo Corporation, Orthofix Medical Inc., Ossatec Benelux BV, BTT Health GmbH, Stimulate Health Inc., ZimVie Inc., Enovis Inc., DePuy Synthes Inc., Smith & Nephew PLC, BioTek Instruments Inc., BioMimetic Therapeutics Inc., Cerament, Cook Medical LLC, Curasan AG, Exactech Inc., Globus Medical Inc., Integra LifeSciences Corporation, Medartis AG, NuVasive Inc., OrthoPediatrics Corp., RTI Surgical Holdings Inc., Wright Medical Group N.V.

North America was the largest region in the bone growth stimulator market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bone growth stimulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bone growth stimulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The bone growth stimulator market consists of sales of electrical and ultrasound bone growth stimulator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.